IMCD/€IMCD
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About IMCD
IMCD N.V. specializes in the distribution and formulation of chemicals and ingredients. Founded in 1995 and headquartered in Rotterdam, the Netherlands, the company operates in numerous countries across the world, serving a wide range of industries. IMCD provides value-added services such as technical support, formulation, marketing, and logistics, leveraging its extensive network to deliver tailored solutions that enhance product performance and facilitate innovation.
- Ticker
- €IMCD
- Sector
- Industrials
- Primary listing
- AEX
- Employees
- 5,237
- Headquarters
- Rotterdam, Netherlands
- Website
- www.imcdgroup.com
IMCD Metrics
BasicAdvanced
€6B
25.92
€3.90
0.96
€1.81
1.79%
Price and volume
Market cap
€6B
Beta
0.96
52-week high
€110.00
52-week low
€68.24
Average daily volume
135K
Dividend rate
€1.81
Financial strength
Current ratio
1.347
Quick ratio
0.851
Long term debt to equity
0.506
Total debt to equity
0.851
Dividend payout ratio (TTM)
46.42%
Interest coverage (TTM)
5.56%
Profitability
EBITDA (TTM)
515.928
Gross margin (TTM)
25.01%
Net profit margin (TTM)
4.63%
Operating margin (TTM)
8.07%
Effective tax rate (TTM)
26.49%
Revenue per employee (TTM)
€950,000
Management effectiveness
Return on assets (TTM)
5.24%
Return on equity (TTM)
11.23%
Valuation
Price to earnings (TTM)
25.919
Price to revenue (TTM)
1.2
Price to book
2.81
Price to tangible book (TTM)
-11.04
Price to free cash flow (TTM)
16.473
Free cash flow yield (TTM)
6.07%
Free cash flow per share (TTM)
6.134
Dividend yield (TTM)
1.79%
Forward dividend yield
1.79%
Growth
Revenue change (TTM)
2.69%
Earnings per share change (TTM)
-14.64%
3-year revenue growth (CAGR)
2.68%
10-year revenue growth (CAGR)
11.37%
3-year earnings per share growth (CAGR)
-8.35%
10-year earnings per share growth (CAGR)
11.51%
3-year dividend per share growth (CAGR)
-8.59%
10-year dividend per share growth (CAGR)
15.19%
What the Analysts think about IMCD
Analyst ratings (Buy, Hold, Sell) for IMCD stock.
Analyst projections of the future price of IMCD stock.
Bulls say / Bears say
After a weak first quarter, IMCD reported organic growth in gross profit and EBITA for the half year, with every region delivering organic gross-profit growth in Q2. That points to a recovery in underlying trading. (IMCD, StockAnalysis)
Three bolt-on deals broadened IMCD’s reach in beauty and personal care, nutrition, and plastics across South Korea, the UK and Ireland, and Thailand. Acquisitions contributed 7% to first-half revenue growth on a constant-currency basis, giving the group another route to expand. (IMCD, European Coatings)
Free cash flow rose 29% to €222 million in the first half of 2026. Stronger cash conversion gives IMCD more capacity to fund investment and manage its debt. (IMCD)
The gross profit margin fell 0.7 percentage points to 24.9% in the first half. Lower-margin acquisitions and product mix contributed, so revenue growth is not translating fully into stronger margins. (European Coatings)
A May JPMorgan downgrade warned that the earnings boost from Middle East-related pricing and supply disruption could fade, while Chinese overcapacity and rising Asian competition weigh on the outlook for 2026–27. (Investing.com)
Net leverage rose to 2.9 times EBITDA in 2025 after weaker earnings and acquisition spending. Fitch expects only gradual deleveraging and says the debt burden limits room for larger deals in the near term. (Fitch Ratings)
Data summarised monthly by Lightyear AI. Last updated on 18 Oct 2026.
IMCD Financial Performance
Revenues and expenses
IMCD Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing IMCD
AllEURUSDGBP
Fund name | Fund size | €IMCD weighting |
|---|---|---|
iShares STOXX Europe 600 Chemicals€EXV7 | €103M | 2.64% |
iShares EURO STOXX Mid€DJMC | €595M | 0.74% |
iShares EURO STOXX Mid Cap£DJMC | €595M | 0.74% |
iShares AEX£IAEX | €781M | 0.60% |
iShares AEX€IAEX | €781M | 0.60% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.